Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chitra Venugopal

Showing results (101-110 of 117) with videos related to

Pageof 12
Sort By:
Nature Communications|August 30, 2020
Wnt activation as a therapeutic strategy in medulloblastomaBranavan Manoranjan, Chitra Venugopal, David Bakhshinyan, et al.
Cell Reports|September 28, 2022
Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastomaMaleeha A Qazi, Sabra K Salim, Kevin R Brown, et al.
Cell Stem Cell|May 29, 2020
The Rational Development of CD133-Targeting Immunotherapies for GlioblastomaParvez Vora, Chitra Venugopal, Sabra Khalid Salim, et al.
Neuron|January 22, 2026
Reactive oligodendrocytes promote glioblastoma progression through CCL5/CCR5-mediated glioma stem cell maintenanceNicholas Mikolajewicz, Kui Zhai, Anish Puri, et al.
Oncotarget|August 29, 2015
STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activationMohini Singh, Neha Garg, Chitra Venugopal, et al.
Cell Reports. Medicine|October 4, 2024
De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastasesAgata M Kieliszek, Daniel Mobilio, Blessing I Bassey-Archibong, et al.
Acta Neuropathologica|September 30, 2022
The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory driversNazanin Tatari, Shahbaz Khan, Julie Livingstone, et al.
Cancer Cell|November 11, 2022
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastomaWilliam D Gwynne, Yujin Suk, Stefan Custers, et al.
Science Translational Medicine|May 13, 2026
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell targetWilliam T Maich, Muhammad Vaseem Shaikh, Anish Puri, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2026
Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell functionAgata M Kieliszek, Erika Apel, Suky Zheng, et al.
Pageof 12

Showing results (101-110 of 117) with videos related to

Sort By:
Pageof 12
Nature Communications|August 30, 2020
Wnt activation as a therapeutic strategy in medulloblastomaBranavan Manoranjan, Chitra Venugopal, David Bakhshinyan, et al.
Cell Reports|September 28, 2022
Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastomaMaleeha A Qazi, Sabra K Salim, Kevin R Brown, et al.
Cell Stem Cell|May 29, 2020
The Rational Development of CD133-Targeting Immunotherapies for GlioblastomaParvez Vora, Chitra Venugopal, Sabra Khalid Salim, et al.
Neuron|January 22, 2026
Reactive oligodendrocytes promote glioblastoma progression through CCL5/CCR5-mediated glioma stem cell maintenanceNicholas Mikolajewicz, Kui Zhai, Anish Puri, et al.
Oncotarget|August 29, 2015
STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activationMohini Singh, Neha Garg, Chitra Venugopal, et al.
Cell Reports. Medicine|October 4, 2024
De novo GTP synthesis is a metabolic vulnerability for the interception of brain metastasesAgata M Kieliszek, Daniel Mobilio, Blessing I Bassey-Archibong, et al.
Acta Neuropathologica|September 30, 2022
The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory driversNazanin Tatari, Shahbaz Khan, Julie Livingstone, et al.
Cancer Cell|November 11, 2022
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastomaWilliam D Gwynne, Yujin Suk, Stefan Custers, et al.
Science Translational Medicine|May 13, 2026
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell targetWilliam T Maich, Muhammad Vaseem Shaikh, Anish Puri, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 17, 2026
Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell functionAgata M Kieliszek, Erika Apel, Suky Zheng, et al.
Pageof 12